OncLive TV

Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses results of a phase II study exploring the efficacy of imatinib (Gleevac) in patients with racist progressive demoed tumors.

Neeraj Agarwal, associate professor in the Division of Oncology, Department of Medicine, director of the Genitourinary Medical Oncology Program, Huntsman Cancer Institute at the University of Utah, discusses some of the adverse events (AEs) associated with checkpoint inhibitors for the treatment of patients with renal cell carcinoma (RCC).

Veronique Leblond, MD, of Pietra - Hospital, Paris, France, discusses the current treatment landscape of chronic lymphocytic leukemia (CLL).

Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Jame Abraham, MD, director of the Breast Oncology Program at Taussig Cancer Institute, and co-director of the Cleveland Clinic Comprehensive Breast Cancer Program, discusses a head cooling system that can be used to limit hair loss attributed to chemotherapy treatment for patients with breast cancer.

Daniel P. Petrylak, MD, professor of Medicine and Urology, Yale Cancer Center, discusses major targeted agents currently being studied in the treatment of patients with bladder cancer.

Judith K. Wolf, MD, chief medical officer of Provista Diagnostics, discusses the capabilities of the blood-based diagnostic test Videssa Breast.

Allison C. Rosenthal, DO, hematology consultant, Mayo Clinic, discusses the FDA approval of of ibrutinib (Imbruvica) as a treatment for patients with marginal zone lymphoma (MZL).

George W. Sledge Jr., MD, professor of Medicine, Chief of the Division of Oncology, Stanford University Medical Center, discusses the use of cyclin-dependent kinase (CDK) 4/6 agents in the treatment of patients with breast cancer.

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses recent advancements in reirradiation treatment for patients with head and neck cancer.

Paul A. Bunn, Jr., MD, professor of Medicine, head of the Division of Medical Oncology at the University of Colorado, discusses combining immunotherapy with chemotherapy and targeted agents in lung cancer.

Steven Horwitz, MD, associate attending physician at Memorial Sloan Kettering Cancer Center, discusses some of the ongoing clinical trials being explored in T-cell lymphoma.

Carl Olsson, MD, Integrated Medical Professionals, compares the efficacy of LHRH agonists with antagonists, which are commonly used to treat patients with prostate cancer.

C. Ola Landgren, MD, PhD, chief of Myeloma Service at Memorial Sloan Kettering Cancer Center, discusses the use of the triplet of daratumumab, bortezomib, and dexamethasone in the treatment of patients with relapsed myeloma.

Mark Stein, MD, medical oncologist, Rutgers Cancer Institute of New Jersey, discusses commercial tests for determining therapies for patients with prostate cancer.

Maurie Markman, MD, president, Medicine and Science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses combination treatments in ovarian cancer.

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses recent progress in the treatment landscape of head and neck cancer.

Robert J. Motzer, MD, attending physician, Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, and professor of Medicine, Weill Medical College, Cornell University, discusses the FDA approval of nivolumab (Opdivo) versus everolimus (Afinitor) for patients with advanced renal cell carcinoma (RCC).

Robert Dreicer, MD, associate director for clinical research and deputy director of the University of Virginia Cancer Center, discusses the questions that surround radium-223.

Andre Goy, MD, MS, chairman and director, chief of Lymphoma, and director of Clinical and Translational Cancer Research at John Theurer Cancer Center, discusses the role of minimal residual disease in the treatment of patients with mantle cell lymphoma.

Graham Jackson, MD, PhD, Northern Institute for Cancer Research, Newcastle University, discusses the benefits of maintenance therapy for patients with multiple myeloma.

Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib as first-line therapy in the treatment of patients with lung cancer.

Danelle James, MD, MAS, head of Oncology at Pharmacyclics, assistant adjunct professor in the Division of Hematology-Oncology at the Chronic Lymphocytic Leukemia Research Consortium, discusses the RESONATE-2 study of ibrutinib (Imbruvica) versus chlorambucil through 5 years of treatment.

Rebecca Kristeleit, BSc, PhD, consultant medical oncologist, University College-London Cancer Institute, discusses the safety profile of rucaparib in the treatment of patients with ovarian cancer.

Rahul Tendulkar, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses post-prostatectomy radiation therapy and its impact on reducing prostate cancer mortality.

Jasmine Rassiwala, MD, resident physician, University of California, San Francisco, discusses the analysis of the “all-comers” downstaging protocol, which investigated whether there were upper limits in tumor burden for successful downstaging of patients with hepatocellular carcinoma to liver transplant.

Jordi Bruix, MD, head of the Barcelona Clinic Liver Cancer at University of Barcelona, discusses positive results with the use of regorafenib as a second-line treatment in patients previously treated with sorafenib in advanced hepatocellular carcinoma.

Michael A. Thompson, MD, PhD, medical director, precision medicine, Vince Lombardi Cancer Clinic, Aurora Health Care, discusses some of the challenges facing the field of multiple myeloma.

In the phase II SARC028 trial, single-agent pembrolizumab (Keytruda) demonstrated antitumor activity in patients with advanced soft tissue and bone sarcomas.

David F. McDermott, MD, Director of Biologic Therapy and Cutaneous Oncology Programs, Hematology and Oncology at the Beth Israel Deaconess Medical Center, discusses the combination of VEGF plus PD-1 in renal cell carcinoma (RCC).